The Million Hearts payment model, which incentivizes healthcare organizations to reduce cardiovascular risk among Medicare beneficiaries, led to a modest but significant reduction in new-onset myocardial infarctions and strokes over five years. The model did not result in a significant increase in Medicare spending, suggesting a cost-effective way to improve cardiovascular health.
Eli Lilly’s donanemab wins FDA approval for Alzheimer’s disease – Pharmaceutical Technology
Kisunla is an amyloid-targeting therapy intended to treat patients with early symptomatic Alzheimer’s disease. Credits: rafapress/Shutterstock.com Eisai and Biogen must now brace for competition as
July 4, 2024